Illumina, Inc. (ILMN, Financial) is the leading provider of next generation DNA sequencing instruments and consumables. During the past quarter, the company reported revenues and earnings that exceeded most estimates, as a result of strong sales of its core sequencing instruments. We believe that Illumina will maintain its dominant position in the DNA sequencing market and that the demand for sequencing will continue to accelerate. We believe that Illumina’s products will play important roles in several rapidly-growing clinical areas, including the markets for cancer research and diagnosis and reproductive health.
From Baron Funds' second quarter commentary.
